EUVIMEDEUVIMED entdecken
Crossref

Evaluating Interim Progression: First Posttherapy 177 Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT

Ashwin Singh Parihar, Farrokh Dehdashti, Niharika Pant, Shubha G Ravindra, Russell Pachynski, Joel Picus, Melissa A Reimers, Amit Bhatt, Hiram Gay, Wilbur Song, Mark Sundermeyer, Amin H Jahromi und 4 weitere

Journal of Nuclear Medicine · 23.07.2026 · jnumed.126.272545

DOI: 10.2967/jnumed.126.272545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 23.07.2026. Verfasst von Ashwin Singh Parihar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri; ashwinp@wustl.edu. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Disease Progression, Dipeptides, Single Photon Emission Computed Tomography Computed Tomography. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyDisease ProgressionDipeptidesSingle Photon Emission Computed Tomography Computed TomographyAntigens, SurfaceHeterocyclic Compounds, 1-RingGlutamate Carboxypeptidase IIProstatic NeoplasmsHeterocyclic CompoundsHumansMaleLutetiumAgedMiddle AgedRadioisotopesTreatment OutcomeProstate-Specific AntigenAged, 80 and overTime Factors

Stichwörter der Autor:innen

177Lu-PSMA-617PSMA PETinterim progressionresponse assessment

Substanzen

DipeptidesLutetiumAntigens, SurfaceHeterocyclic Compounds, 1-RingGlutamate Carboxypeptidase IILutetium-177FOLH1 protein, humanlutetium (177Lu) vipivotide tetraxetanRadioisotopesHeterocyclic Compounds

Autor:innen und Institutionen

  • Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri; ashwinp@wustl.edu.
  • Siteman Cancer Center, St. Louis, Missouri.
  • Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri.
  • Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri; and.
  • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.

Zitieren

APA

Parihar, A. S., Dehdashti, F., Pant, N., Ravindra, S. G., Pachynski, R., Picus, J., Reimers, M. A., Bhatt, A., Gay, H., Song, W., Sundermeyer, M., Jahromi, A. H., Swingle, C. A., Michalski, J. M., Wahl, R. L., & Prasad, V. (2026). Evaluating Interim Progression: First Posttherapy 177 Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT. Journal of Nuclear Medicine, jnumed.126.272545. https://doi.org/10.2967/jnumed.126.272545

Vancouver

Parihar AS, Dehdashti F, Pant N, Ravindra SG, Pachynski R, Picus J, et al. Evaluating Interim Progression: First Posttherapy 177 Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT. Journal of Nuclear Medicine. 2026:jnumed.126.272545. doi:10.2967/jnumed.126.272545

BibTeX
@article{Parihar2026,
  author = {Parihar, Ashwin Singh and Dehdashti, Farrokh and Pant, Niharika and Ravindra, Shubha G and Pachynski, Russell and Picus, Joel and Reimers, Melissa A and Bhatt, Amit and Gay, Hiram and Song, Wilbur and Sundermeyer, Mark and Jahromi, Amin H and Swingle, Christopher A and Michalski, Jeff M and Wahl, Richard L and Prasad, Vikas},
  title = {Evaluating Interim Progression: First Posttherapy 177 Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.126.272545},
  doi = {10.2967/jnumed.126.272545}
}
Kostenlos starten →